A multimarker multi‐time point‐based risk stratification strategy in acute heart failure: results from the <scp>RELAX‐AHF</scp> trial

2017

Biomed. Res. Ther.

Heart failure (HF) is considered a leading cause of death in patients with established cardiovascular (CV) and metabolic diseases. Although current treatment strategy has improved survival rate and clinical outcomes of HF, the HF prevalence exhibits growth especially in older patients' population and survivors after coronary atherothrombotic events. Current clinical guidelines regarding treatment and prevention of HF claim the role of biological markers as pretty easy and powerful tool for diagnosis, risk stratification, and prognostication of HF. However, there is not clear whether all these biological markers are able to equally predict CV death and HF-related outcomes in patients with acute and chronic HF as well as in various phenotypes of HF. The aim of the review is to discuss a role of in risk stratification and individual treatment in patients with different phenotypes of HF.

Section: Growth Differentiation Factor-15mentioning

confidence: 99%

Up-to-date clinical approaches of biomarkers’ use in heart failure

2017

Biomed. Res. Ther.

“…There is strong evidence regarding being tight interrelationship between circulating level of GDF-15 and HF signs and symptoms, reduced left ventricular ejection fraction [27]. Although serial biomarker evaluation has not showed superiority of incremental predictive ability in GDF-15 versus natriuretic peptides in acute HF [28], in chronic HF multiple marker strategy based on GDF-15, galectin-3 and natriuretic peptides might exhibit several advantages before conventional approach in ability to predict all-cause mortality, CV mortality and HF-related outcomes in outpatients with HF [29,30].…”

Section: Short Communicationmentioning

confidence: 99%

Novel Biomarkers in Prediction of Heart Failure Related Outcomes: From Bench to Bedside

2017

Intern Med

Heart failure (HF) remains a global burden for patients with established cardiovascular (CV) disease. It has been postulated that underlying mechanisms of nature evolution of HF might be identified by measurement of some biomarker reflected various pathophysiological stages of cardiac dysfunction. In this way, cardiac biomarkers affected biomechanical stress, cardiac injury, fluid overload, inflammatory reaction, may be useful for prediction of development, progression, and prognosis of HF. The short communication is depicted to discussion around perspectives to use in routine HF clinical practice new biomarkers, i.e. procalcitonin, copeptin, heart-type fatty acidbinding protein; growth differentiation factor 15. It has concluded that these biomarkers are needed to be investigated in details, while there is suggestion that multiple biomarker models would be better in prediction HF evolution and outcomes than even single brand new biomarker.

“…Interestingly, GDF-15 is able to enhance prognostication of NPs beyond traditional CV risk factor, and echocardiography parameters in individuals without known CV disease [12] and acute/chronic HF [20].…”

Section: Introductionmentioning

confidence: 99%

Growth-Differentiation Factor-15 as Additional Prognostic Biomarkers in Heart Failure

2017

Metabolomics

Heart Failure (HF) remains to be a leading factor of cardiovascular morbidity and mortality. Although risk stratification of HF is promising prediction care, there are several controversies regarding choosing more optimal combinations of biomarkers and method (single versus serial measurements) of biomarker use in routine clinical practice. Growth differentiation factor-15 (GDF-15) is considered a biomarker associated with cardiac/vascular remodeling, oxidative stress, fibrosis and inflammation that were proposed to stratify HF patients at risk of death. It has been suggested that GDF-15 adding to natriuretic peptides or other conventional biomarkers (soluble ST2, cardiac troponins and galectin-3) might improve discriminative value of entire predictive models. The short communication is depicted the discussion about the perspectives of clinical use of GDF-15 in risk stratification of HF.